Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection.

Simon, Hans-Uwe; Karaulov, Alexander V; Bachmann, Martin F. (2020). Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection. International archives of allergy and immunology, 181(8), pp. 624-628. Karger 10.1159/000509368

	Text Simon_Strategies to prevent SARS-CoV-2-Mediated.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (464kB)
Preview	Text COVID-19_review_HUS2_Manuskript.pdf - Accepted Version Available under License Publisher holds Copyright. Download (522kB) | Preview
Preview	Text Manuskript.pdf - Accepted Version Available under License Publisher holds Copyright. Download (222kB) | Preview

A vaccine to protect against COVID-19 is urgently needed. Such a vaccine should efficiently induce high-affinity neutralizing antibodies which neutralize SARS-CoV-2, the cause of COVID-19. However, there is a concern regarding both vaccine-induced eosinophilic lung disease and eosinophil-associated Th2 immunopotentiation following infection after vaccination. Here, we review the anticipated characteristics of a COVID-19 vaccine to avoid vaccine-associated eosinophil immunopathology.

Interest & Impact

Downloads

37 since deposited on 29 Jun 2020
12 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item